New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL

Abstract CD19‐directed chimeric antigen receptor T‐cell therapy (CAR‐T) represents a significant advancement for patients with relapsed/refractory large B‐cell lymphoma (LBCL). Long‐term follow‐up confirms durable remissions in nearly half of the patients, a population that was previously estimated...

Full description

Bibliographic Details
Main Authors: Madiha Iqbal, Bipin N Savani, Mehdi Hamadani
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:eJHaem
Subjects:
allogeneic CAR
CAR‐T
dual CAR
follicular lymphoma
lymphoma
mantle cell
Online Access:https://doi.org/10.1002/jha2.323

Similar Items

Similar Items